X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
male (8) 8
middle aged (6) 6
aged (5) 5
cancer (5) 5
oncology (5) 5
abridged index medicus (4) 4
adult (4) 4
metastasis (4) 4
prostate cancer (4) 4
abiraterone acetate (3) 3
analysis (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
chemotherapy (3) 3
docetaxel (3) 3
men (3) 3
neoplasm metastasis (3) 3
oncology, experimental (3) 3
prednisone (3) 3
research (3) 3
survival (3) 3
aged, 80 and over (2) 2
allergies (2) 2
allergy (2) 2
allergy and immunology (2) 2
animals (2) 2
antineoplastic agents - therapeutic use (2) 2
cancer therapies (2) 2
care and treatment (2) 2
cell degranulation (2) 2
clinical trials (2) 2
clinical-trials (2) 2
disease-free survival (2) 2
drug administration schedule (2) 2
enzalutamide (2) 2
female (2) 2
hematology, oncology and palliative medicine (2) 2
immunology (2) 2
kaplan-meier estimate (2) 2
metaanalysis (2) 2
mice (2) 2
mitoxantrone (2) 2
orchiectomy (2) 2
prostate-specific antigen - blood (2) 2
prostatic neoplasms - drug therapy (2) 2
prostatic neoplasms, castration-resistant - drug therapy (2) 2
prostatic neoplasms, castration-resistant - pathology (2) 2
rodents (2) 2
survival rate (2) 2
treatment outcome (2) 2
urology (2) 2
urology & nephrology (2) 2
200-tev (1) 1
abiraterone acetate - administration & dosage (1) 1
abiraterone acetate - blood (1) 1
abiraterone acetate - therapeutic use (1) 1
accelerated methotrexate (1) 1
accreditation (1) 1
acetat (1) 1
acetates (1) 1
acetic acid (1) 1
activation (1) 1
adaptation (1) 1
adaptation, psychological - physiology (1) 1
adenocarcinoma (1) 1
adjustment (1) 1
administration, oral (1) 1
age (1) 1
airway mucosal eosinophils (1) 1
allergens - administration & dosage (1) 1
allergens - immunology (1) 1
allergic inflammation (1) 1
and cisplatin (1) 1
androgen antagonists - administration & dosage (1) 1
androgen antagonists - adverse effects (1) 1
androgen antagonists - therapeutic use (1) 1
androgen receptor antagonists (1) 1
androgen receptor antagonists - pharmacology (1) 1
androgen receptor antagonists - therapeutic use (1) 1
androgen-deprivation therapy (1) 1
angiogenesis inhibitors (1) 1
animal models (1) 1
antiandrogen (1) 1
antibodies, monoclonal (1) 1
antibodies, monoclonal - chemistry (1) 1
antigen-presenting cells (1) 1
antineoplastic agents - blood (1) 1
antineoplastic agents, hormonal - administration & dosage (1) 1
antineoplastic agents, hormonal - adverse effects (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antitumor-activity (1) 1
asthma (1) 1
astrophysics (1) 1
atopic-dermatitis (1) 1
aua guideline (1) 1
axis (1) 1
biochemical assays (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Journal Article
Journal of allergy and clinical immunology, ISSN 0091-6749, 2015, Volume 135, Issue 2, pp. 477 - 487.e1
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 975 - 985
Journal Article
Journal of allergy and clinical immunology, ISSN 0091-6749, 2012, Volume 130, Issue 3, pp. 572 - 584
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 549 - 558
Journal Article
Nature communications, ISSN 2041-1723, 2015, Volume 6, Issue 1, p. 6336
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 08/2012, Volume 118, Issue 16, pp. 3920 - 3927
BACKGROUND: Meta‐analysis data demonstrate a 5% absolute survival benefit for neoadjuvant chemotherapy (NAC) using cisplatin‐based combination regimens in the... 
muscle‐invasive | neoadjuvant | vinblastine | bladder cancer | dose‐intense | and cisplatin (AMVAC) | accelerated methotrexate | doxorubicin | chemotherapy | transitional cell carcinoma | muscle-invasive | dose-intense | SURVIVAL | METAANALYSIS | UROTHELIAL CARCINOMA | STAGE | CANCER | PHASE-III TRIAL | GEMCITABINE PLUS CISPLATIN | ONCOLOGY | RADICAL CYSTECTOMY | UPDATE | PARADIGM | Carcinoma, Transitional Cell - mortality | Recurrence | Humans | Middle Aged | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Urinary Bladder Neoplasms - pathology | Adult | Female | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Muscle Neoplasms - drug therapy | Doxorubicin - administration & dosage | Urinary Bladder Neoplasms - mortality | Neoplasm Invasiveness | Combined Modality Therapy | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Cystectomy | Carcinoma, Transitional Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Transitional Cell - drug therapy | Methotrexate - administration & dosage | Aged | Carcinoma, Transitional Cell - surgery | Adenocarcinoma | Neoadjuvant therapy | Care and treatment | Chemotherapy | Usage | Bladder cancer | Meta-analysis | Cancer | Index Medicus | Abridged Index Medicus
Journal Article